$52.82
0.47% yesterday
Nasdaq, Aug 21, 10:11 pm CET
ISIN
CH0334081137
Symbol
CRSP

CRISPR Therapeutics AG Target price 2025 - Analyst rating & recommendation

CRISPR Therapeutics AG Classifications & Recommendation:

Buy
63%
Hold
34%
Sell
3%

CRISPR Therapeutics AG Price Target

Target Price $79.56
Price $52.82
Potential
Number of Estimates 27
27 Analysts have issued a price target CRISPR Therapeutics AG 2026 . The average CRISPR Therapeutics AG target price is $79.56. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 35 analysts: 22 Analysts recommend CRISPR Therapeutics AG to buy, 12 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the CRISPR Therapeutics AG stock has an average upside potential 2026 of . Most analysts recommend the CRISPR Therapeutics AG stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 37.31 47.88
89.95% 28.32%
EBITDA Margin -1,198.90% -1,031.51%
2,095.58% 13.96%
Net Margin -981.64% -1,020.09%
2,272.21% 3.92%

28 Analysts have issued a sales forecast CRISPR Therapeutics AG 2025 . The average CRISPR Therapeutics AG sales estimate is

$47.9m
Unlock
. This is
25.83% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$150m 294.61%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $37.3m 89.95%
2025
$47.9m 28.32%
Unlock
2026
$176m 268.05%
Unlock
2027
$411m 133.11%
Unlock
2028
$887m 115.88%
Unlock
2029
$2.3b 157.58%
Unlock
2030
$6.1b 167.16%
Unlock
2031
$1.4b 77.79%
Unlock
2032
$1.7b 25.90%
Unlock

10 Analysts have issued an CRISPR Therapeutics AG EBITDA forecast 2025. The average CRISPR Therapeutics AG EBITDA estimate is

$-494m
Unlock
. This is
12.95% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-354m 19.04%
Unlock
, the lowest is
$-604m 38.06%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-447m 120.68%
2025
$-494m 10.41%
Unlock
2026
$-449m 9.03%
Unlock
2027
$-359m 20.01%
Unlock
2028
$-12.8m 96.43%
Unlock
2029
$258m 2,115.71%
Unlock
2030
$463m 79.24%
Unlock
2031
$914m 97.36%
Unlock
2032
$1.4b 48.37%
Unlock

EBITDA Margin

2024 -1,198.90% 2,095.58%
2025
-1,031.51% 13.96%
Unlock
2026
-254.95% 75.28%
Unlock
2027
-87.49% 65.68%
Unlock
2028
-1.45% 98.34%
Unlock
2029
11.31% 880.00%
Unlock

31 CRISPR Therapeutics AG Analysts have issued a net profit forecast 2025. The average CRISPR Therapeutics AG net profit estimate is

$-488m
Unlock
. This is
4.40% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-354m 24.42%
Unlock
, the lowest is
$-581m 24.23%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-366m 138.43%
2025
$-488m 33.35%
Unlock
2026
$-403m 17.51%
Unlock
2027
$-314m 22.11%
Unlock
2028
$20.3m 106.48%
Unlock
2029
$578m 2,740.41%
Unlock
2030
$2.2b 284.14%
Unlock
2031
$341m 84.62%
Unlock
2032
$449m 31.56%
Unlock

Net Margin

2024 -981.64% 2,272.21%
2025
-1,020.09% 3.92%
Unlock
2026
-228.64% 77.59%
Unlock
2027
-76.40% 66.59%
Unlock
2028
2.29% 103.00%
Unlock
2029
25.30% 1,004.80%
Unlock
2030
36.37% 43.75%
Unlock
2031
25.19% 30.74%
Unlock
2032
26.32% 4.49%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -4.34 -5.53
123.71% 27.42%
P/E negative
EV/Sales 64.86

31 Analysts have issued a CRISPR Therapeutics AG forecast for earnings per share. The average CRISPR Therapeutics AG EPS is

$-5.53
Unlock
. This is
2.98% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-4.00 25.51%
Unlock
, the lowest is
$-6.58 22.53%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-4.34 123.71%
2025
$-5.53 27.42%
Unlock
2026
$-4.56 17.54%
Unlock
2027
$-3.55 22.15%
Unlock
2028
$0.23 106.48%
Unlock
2029
$6.54 2,743.48%
Unlock
2030
$25.11 283.94%
Unlock
2031
$3.86 84.63%
Unlock
2032
$5.08 31.61%
Unlock

P/E ratio

Current -9.88 35.35%
2025
-9.60 2.86%
Unlock
2026
-11.64 21.25%
Unlock
2027
-14.95 28.44%
Unlock
2028
230.63 1,642.68%
Unlock
2029
8.12 96.48%
Unlock
2030
2.11 74.01%
Unlock
2031
13.74 551.18%
Unlock
2032
10.44 24.02%
Unlock

Based on analysts' sales estimates for 2025, the CRISPR Therapeutics AG stock is valued at an EV/Sales of

64.86
Unlock
and an P/S ratio of
100.82
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 81.62 696.29%
2025
64.86 20.53%
Unlock
2026
17.62 72.83%
Unlock
2027
7.56 57.10%
Unlock
2028
3.50 53.68%
Unlock
2029
1.36 61.18%
Unlock
2030
0.51 62.57%
Unlock
2031
2.29 350.36%
Unlock
2032
1.82 20.58%
Unlock

P/S ratio

Current 126.85 529.48%
2025
100.82 20.53%
Unlock
2026
27.39 72.83%
Unlock
2027
11.75 57.10%
Unlock
2028
5.44 53.68%
Unlock
2029
2.11 61.18%
Unlock
2030
0.79 62.57%
Unlock
2031
3.56 350.34%
Unlock
2032
2.83 20.57%
Unlock

Current CRISPR Therapeutics AG Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Aug 07 2025
Barclays
Locked
Locked
Locked Aug 06 2025
Chardan Capital
Locked
Locked
Locked Aug 05 2025
RBC Capital
Locked
Locked
Locked Aug 05 2025
B of A Securities
Locked
Locked
Locked Jul 22 2025
Needham
Locked
Locked
Locked Jul 08 2025
Clear Street
Locked
Locked
Locked Jun 27 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 07 2025
Locked
Barclays:
Locked
Locked
Aug 06 2025
Locked
Chardan Capital:
Locked
Locked
Aug 05 2025
Locked
RBC Capital:
Locked
Locked
Aug 05 2025
Locked
B of A Securities:
Locked
Locked
Jul 22 2025
Locked
Needham:
Locked
Locked
Jul 08 2025
Locked
Clear Street:
Locked
Locked
Jun 27 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today